Literature DB >> 12033376

Percutaneous delivery of thalidomide and its N-alkyl analogs.

Colleen Goosen1, Timothy J Laing, Jeanetta du Plessis, Theunis C Goosen, Guang-Wei Lu, Gordon L Flynn.   

Abstract

PURPOSE: The purpose of this study was to determine the permeation parameters of thalidomide and three of its N-alkyl analogs and to establish a correlation between the physicochemical properties of these compounds and their percutaneous rates of absorption.
METHODS: In vitro permeation studies were performed from buffer, n-alkanols and various mixed components using vertical Franz diffusion cells fitted with human epidermal membranes.
RESULTS: Measured steady-state fluxes indicate that N-methyl thalidomide is a far better penetrant of human skin than the "parent molecule". However, fluxes through skin drop off markedly from that of the methylated compound when the chain length is extended to propyl and pentyl. However, they remain well above the flux of thalidomide, which is less than 0.025 microg/cm2/h.
CONCLUSIONS: The best skin permeant of this series was the N-methyl analog, which also exhibited the highest water (buffer) solubility compared to thalidomide, and the N-propyl and N-pentyl analogs. The N-propyl and N-pentyl analogs were more lipid soluble and exhibited higher partition coefficient values than the N-methyl analog. From all the permeability data using buffer, a series of n-alkanols and various combinations of solvents and enhancers as vehicles, the more water-soluble compound and not the more lipid soluble one was the best skin permeant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12033376     DOI: 10.1023/a:1015183310000

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Skin penetration of nonsteroidal antiinflammatory drugs out of a lipophilic vehicle: influence of the viable epidermis.

Authors:  B P Wenkers; B C Lippold
Journal:  J Pharm Sci       Date:  1999-12       Impact factor: 3.534

2.  The selection of non-steroidal anti-inflammatory agents for dermal delivery.

Authors:  J Hadgraft; J du Plessis; C Goosen
Journal:  Int J Pharm       Date:  2000-10-10       Impact factor: 5.875

3.  Predicting skin permeability.

Authors:  R O Potts; R H Guy
Journal:  Pharm Res       Date:  1992-05       Impact factor: 4.200

4.  A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs.

Authors:  J A Cordero; L Alarcon; E Escribano; R Obach; J Domenech
Journal:  J Pharm Sci       Date:  1997-04       Impact factor: 3.534

5.  Effects of freezing on human skin permeability.

Authors:  S M Harrison; B W Barry; P H Dugard
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

6.  Permeabilities of alkyl p-aminobenzoates through living skin equivalent and cadaver skin.

Authors:  S D Roy; J Fujiki; J S Fleitman
Journal:  J Pharm Sci       Date:  1993-12       Impact factor: 3.534

7.  Skin permeability of various non-steroidal anti-inflammatory drugs in man.

Authors:  T Yano; A Nakagawa; M Tsuji; K Noda
Journal:  Life Sci       Date:  1986-09-22       Impact factor: 5.037

8.  Thalidomide. A promising new treatment for rheumatoid arthritis.

Authors:  O Gutiérrez-Rodríguez
Journal:  Arthritis Rheum       Date:  1984-10

9.  Delivery of theophylline into excised human skin from alkanoic acid solutions: a "push-pull" mechanism.

Authors:  R Kadir; D Stempler; Z Liron; S Cohen
Journal:  J Pharm Sci       Date:  1987-10       Impact factor: 3.534

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  2 in total

1.  Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.

Authors:  Colleen Goosen; Timothy J Laing; Jeanetta du Plessis; Theunis C Goosen; Tharaknath B Rao; Gordon L Flynn
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 2.  Design for optimized topical delivery: Prodrugs and a paradigm change.

Authors:  Kenneth B Sloan; Scott C Wasdo; Jarkko Rautio
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.